PTG Stock Overview
A biotechnology company, develops therapies for autoimmune diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Poltreg S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł48.00 |
| 52 Week High | zł57.80 |
| 52 Week Low | zł43.40 |
| Beta | 0.95 |
| 11 Month Change | -5.88% |
| 3 Month Change | -2.04% |
| 1 Year Change | -10.78% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.57% |
Recent News & Updates
Recent updates
Will Poltreg (WSE:PTG) Spend Its Cash Wisely?
Sep 10
Is Poltreg (WSE:PTG) In A Good Position To Invest In Growth?
Mar 13Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation
Jun 21We Think Poltreg (WSE:PTG) Can Afford To Drive Business Growth
Oct 05Here's Why We're Not Too Worried About Poltreg's (WSE:PTG) Cash Burn Situation
Jun 16Poltreg (WSE:PTG) Is In A Good Position To Deliver On Growth Plans
Feb 24Shareholder Returns
| PTG | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -5.1% | -4.5% | -3.3% |
| 1Y | -10.8% | -16.2% | 1.1% |
Return vs Industry: PTG exceeded the Polish Biotechs industry which returned -16.2% over the past year.
Return vs Market: PTG underperformed the Polish Market which returned 1.1% over the past year.
Price Volatility
| PTG volatility | |
|---|---|
| PTG Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: PTG has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: PTG's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 26 | Piotr Trzonkowsk | poltreg.tech |
Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases. It engages in the research and development of therapies for the treatment of type 1 diabetes in children, and multiple sclerosis. The company was incorporated in 2016 and is based in Gdansk, Poland.
Poltreg S.A. Fundamentals Summary
| PTG fundamental statistics | |
|---|---|
| Market cap | zł226.64m |
| Earnings (TTM) | -zł15.65m |
| Revenue (TTM) | zł900.00k |
248.7x
P/S Ratio-14.3x
P/E RatioIs PTG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTG income statement (TTM) | |
|---|---|
| Revenue | zł900.00k |
| Cost of Revenue | zł3.03m |
| Gross Profit | -zł2.13m |
| Other Expenses | zł13.52m |
| Earnings | -zł15.65m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | -3.36 |
| Gross Margin | -236.78% |
| Net Profit Margin | -1,738.56% |
| Debt/Equity Ratio | 0% |
How did PTG perform over the long term?
See historical performance and comparison